Phillip Engel

Comprehensive Blood Panel Results & Trend Analysis
DOB: 04/12/1967 · Age: 58
Collected: 2026-04-09
Reported: 2026-04-09
Lab: LabCorp · Fasting: No
Key Findings at a Glance
FERRITIN
12
ref 30-400 · CRITICAL LOW
APOB
92
ref <90 · BORDERLINE*
HDL
38
ref >39 · LOW
HS-CRP
0.62
ref 0.00-3.00 · LOW RISK
HBA1C
5.4%
ref 4.8-5.6 · OPTIMAL
FASTING INSULIN
4.9
ref 2.6-24.9 · EXCELLENT
PSA
0.9
ref 0.0-4.0 · NORMAL
LP(A)
37.6
ref <75.0 · NORMAL
TESTOSTERONE
1165
ref 264-916 · TRT EXPECTED
ESTRADIOL
30
ref 8.0-35.0 · OPTIMAL
CREATININE
1.42
ref 0.76-1.27 · CREATINE ARTIFACT
VITAMIN D
59.7
ref 30.0-100.0 · OPTIMAL
Historical Trends

Ferritin (ng/mL)

HDL Cholesterol (mg/dL)

Hemoglobin (g/dL)

ApoB (mg/dL)

Total Cholesterol / LDL / Triglycerides

Estradiol Sensitive (pg/mL)

Creatinine (mg/dL) & eGFR

Testosterone — Total (ng/dL)

Complete Blood Count (CBC)
TestResultPreviousReferenceStatus
WBC 5.5 4.1 (04/2025) 3.4-10.8 Normal
RBC 5.51 5.18 (04/2025) 4.14-5.80 Normal
Hemoglobin 13.8 14.6 (04/2025) 13.0-17.7 Normal
Hematocrit 44.8% 45.1% (04/2025) 37.5-51.0 Normal
MCV 81 87 (04/2025) 79-97 Normal
MCH 25 28.2 (04/2025) 26.6-33.0 Low
MCHC 30.8 32.4 (04/2025) 31.5-35.7 Low
RDW 16.1% 13.4% (04/2025) 11.6-15.4 High
Platelets 228 194 (04/2025) 150-450 Normal
Comprehensive Metabolic Panel
TestResultPreviousReferenceStatus
Glucose 83 74 (08/2025) 70-99 Normal
BUN 21 23 (08/2025) 6-24 Normal
Creatinine 1.42 1.04 (08/2025) 0.76-1.27 Creatine
eGFR 57 83 (08/2025) >59 Creatine
Sodium 137 139 (08/2025) 134-144 Normal
Potassium 4.7 4.3 (08/2025) 3.5-5.2 Normal
Chloride 101 101 (08/2025) 96-106 Normal
CO2 24 22 (08/2025) 20-29 Normal
Calcium 9 9.2 (08/2025) 8.7-10.2 Normal
Protein, Total 6.7 6.7 (08/2025) 6.0-8.5 Normal
Albumin 4.5 4.6 (08/2025) 3.8-4.9 Normal
Globulin 2.2 2.1 (08/2025) 1.5-4.5 Normal
Bilirubin, Total 0.4 0.3 (08/2025) 0.0-1.2 Normal
Alk Phosphatase 54 53 (08/2025) 47-123 Normal
AST (SGOT) 28 24 (08/2025) 0-40 Normal
ALT (SGPT) 27 29 (08/2025) 0-44 Normal
Cardiovascular & Lipids
TestResultPreviousReferenceStatus
Total Cholesterol 170 180 (04/2025) 100-199 Normal
Triglycerides 91 62 (04/2025) 0-149 Normal
HDL Cholesterol 38 38 (04/2025) >39 Low
VLDL 15 15 (07/2024) 5-40 Normal
LDL Calculated 117 123 (07/2024) 0-99 High
LDL/HDL Ratio 3.1 0.0-3.6 Normal
Apolipoprotein B 92 102 (06/2024) <90 Borderline*
Lipoprotein(a) 37.6 38.5 (06/2024) <75.0 Normal
hs-CRP 0.62 0.25 (06/2024) 0.00-3.00 Low Risk

Lipid Context Note

ApoB and LDL values reflect only ~2 weeks off Pravastatin. True unmedicated baseline will be higher. Recheck lipids + ApoB in 6-8 weeks after restarting statin therapy. With documented coronary artery disease (cath Aug 2025), target ApoB is <80 mg/dL, ideally <70.

Hormones & Thyroid
TestResultPreviousReferenceStatus
Testosterone, Total 1165 448 (08/2025) 264-916 TRT Expected
Free Testosterone 32.7 8.8 (08/2025) 7.2-24.0 TRT Expected
Estradiol, Sensitive 30 17.9 (08/2025) 8.0-35.0 Optimal
TSH 1.98 1.6 (04/2025) 0.450-4.500 Normal
Free T3 3 2.8 (04/2025) 2.0-4.4 Normal
Metabolic Health
TestResultPreviousReferenceStatus
Hemoglobin A1c 5.4% 5% (06/2024) 4.8-5.6 Optimal
Fasting Insulin 4.9 2.6-24.9 Excellent
Glucose 83 74 (08/2025) 70-99 Normal
Liver, Iron & Nutrients
TestResultPreviousReferenceStatus
GGT 30 0-65 Normal
AST (SGOT) 28 24 (08/2025) 0-40 Normal
ALT (SGPT) 27 29 (08/2025) 0-44 Normal
Ferritin 12 22 (06/2024) 30-400 Critical Low
Vitamin D, 25-OH 59.7 51.9 (06/2024) 30.0-100.0 Optimal
Prostate
TestResultPreviousReferenceStatus
PSA Total 0.9 0.9 (04/2025) 0.0-4.0 Normal
Action Items
  • 1. Start Iron Supplementation — Immediately
    Ferrex 150 (polysaccharide-iron complex), 1 capsule every other day on empty stomach with vitamin C. Take 2 hours away from berberine, calcium, magnesium, coffee. Switch multivitamin to version with iron. Recheck ferritin in 8-12 weeks.
  • 2. Restart Statin Therapy — This Week
    Contact prescribing physician. Resume Pravastatin. Discuss adding Ezetimibe to reach ApoB target <80 (ideally <70) given documented coronary artery disease. Recheck lipid panel + ApoB 6-8 weeks after restarting.
  • 3. Fecal Immunochemical Test (FIT) — Within 1-2 Weeks
    Rule out occult GI blood loss as cause of declining ferritin. Order through Taylor at Marek Health (LabCorp) or purchase OTC. Daily aspirin use increases GI microbleed risk. If positive, GI referral warranted.
  • 4. Lipid + ApoB Recheck — 6-8 Weeks
    After resuming statin, retest Lipid Panel + ApoB through Taylor at Marek. ~$40 estimated. Goal: confirm ApoB <80 on treatment.
  • 5. Ferritin Recheck — 8-12 Weeks
    Confirm iron supplementation is working. Target: ferritin >50. If no improvement, investigate absorption issues or occult blood loss further.
  • 6. Maintain Current Protocol
    DIM 200mg + Calcium D-Glucarate 500mg → estradiol well controlled at 30.0. TRT microdosing protocol stable. D3+K2 supplementation achieving target. Berberine + milk thistle → GGT/liver enzymes clean. No changes needed.

Interpretation Context

Creatinine / eGFR: Flagged values (1.42 / 57) are artifacts of 10g daily creatine monohydrate supplementation, not true kidney dysfunction. BUN normal at 21, BUN/Creatinine ratio normal at 15. A Cystatin C test would provide creatine-independent kidney assessment if verification desired.

Testosterone / Free T: Flagged high values expected on exogenous TRT protocol (daily microdosing ~30mg cypionate/enanthate). HPTA fully suppressed after 15+ years. No diurnal variation. Levels reflect steady-state, not a peak or trough.

Previous Testosterone (448 ng/dL, 08/2025): That draw likely occurred during a protocol adjustment or missed doses — current 1165 reflects the active daily microdosing protocol.

Iron Depletion Pattern: MCH low (25.0), MCHC low (30.8), RDW high (16.1), MCV declining (87→81), hemoglobin trending down (17.9→13.8 over 2 years), ferritin critically low (12). Classic early iron deficiency anemia developing. Hemoglobin still in range but trajectory is concerning. History of regular blood donations (stopped mid-2025) plus daily aspirin and supplement stack competing with iron absorption are likely contributors.